US Equities Analysis

MRNA — Moderna

MRNA Price Chart FCF Yield Dividend Yield Price / Earnings Price / Book EV / EBITDA EV / NOPAT Consensus EPS Broker Sentiment EBITDA Margin EBIT Margin ROIC & ROE Capital Turnover Capex & WC / Sales Net Debt / Equity Price and 100d MA Relative to Index Relative to MSCI


1. Industry Fundamentals

1.1 Cyclicality

The company operates in a cyclical industry sensitive to macroeconomic conditions. Revenue and earnings tend to correlate with broader economic cycles, with periods of expansion driving growth and contractions creating headwinds. Current market capitalisation: 18.25B.

1.2 Competition

The industry is moderately competitive with established players and meaningful barriers to entry. Beta of 1.03 suggests moderate market sensitivity. Competitive advantages stem from brand, scale, or regulatory moats.

1.3 Technology

Key technology drivers include digital transformation, operational efficiency, automation. Companies that invest in R&D and adopt new technologies tend to gain market share. The pace of technological change creates both opportunities for innovation and risks of disruption.


2. Company Fundamentals

2.1 Competitiveness

Metric Value
Operating Margins -131.1%
Profit Margins -143.55%
Return on Equity -36.56%
Return on Assets -13.09%
Free Float 0.37B
Short Int % Utilisation 17.82%

2.2 Growth

Metric Value
Revenue Growth 260.2%
Free Cash Flow -0.02B
EBITDA -6.24 (Ratio)
Enterprise Value 14.34B
EV/Revenue 6.45
EV/EBITDA -6.24

Revenue growth of 260.2% places the company in a high-growth category.

2.3 Management

Role Metric
Consensus Rating N/A

2.4 Return

Metric Value
Expected Return (Ann.) -9.36%
Risk / Std Dev (Ann.) 66.45%
Sharpe Ratio (rf=4.5%) -0.21
Beta 1.03

2.5 Valuation

Metric Value
P/E (Forward) -10.94
Price/Book 3.27
EV/Revenue 6.45
EV/EBITDA -6.24
FCF Yield (%) -0.08%
Price / Book 3.27
Enterprise Value / EBITDA -8.83

Forward P/E is negative (trailing earnings are loss-making) — the valuation is based on recovery expectations.

2.6 Return Outlook

The stock’s historical risk-return profile shows an annualised expected return of -9.4% with annualised volatility of 66.5%, yielding a Sharpe ratio of -0.21 (rf=4.5%). The risk-adjusted return is below the risk-free rate, suggesting compensation for risk may be inadequate. With a beta of 1.0, the stock moves broadly in line with the market.


us-equitystockequitymrnahealth-carebiotechnologynasdaq